GT BIOPHARMA, INC. Cash and Cash Equivalents
GT BIOPHARMA, INC. (GTBP) had Cash and Cash Equivalents of $4.96 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-14
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $4.96M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $8.92M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $6.81M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $2.53M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $4.96M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $8.92M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $6.81M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $2.53M 10-Q/A · filed 2026-03-06 |
| 2025-06-30 | $5.23M 10-Q/A · filed 2026-03-06 |
| 2025-03-31 | $2.37M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $3.95M 10-Q/A · filed 2026-03-06 |
| 2024-09-30 | $6.42M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $9.25M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.95M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.08M 10-K · filed 2025-02-21 |
| 2023-09-30 | $2.65M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $2.77M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $2.04M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $5.67M 10-K · filed 2024-03-26 |
| 2021-12-31 | $8.97M 10-K · filed 2023-03-30 |
| 2021-06-30 | $39.50M 10-Q/A · filed 2021-12-29 |
| 2021-03-31 | $27.55M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $5.30M 10-Q · filed 2021-05-17 |
| 2020-09-30 | $350.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $851.00K 10-Q/A · filed 2020-08-18 |
| 2020-03-31 | $5.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $28.00K 10-K · filed 2021-04-16 |
| 2019-09-30 | $313.00K 10-Q · filed 2020-11-13 |
| 2019-06-30 | $264.00K 10-Q/A · filed 2020-08-18 |
| 2019-03-31 | $51.00K 10-Q · filed 2020-05-15 |
| 2018-12-31 | $60.00K 10-K · filed 2021-04-16 |
| 2018-09-30 | $1.23M 10-Q · filed 2019-11-14 |
| 2018-06-30 | $1.10M 10-Q · filed 2019-08-14 |
| 2018-03-31 | $2.87M 10-Q · filed 2019-05-15 |
| 2017-12-31 | $576.00K 10-K · filed 2020-03-27 |
| 2017-09-30 | $2.73M 10-Q · filed 2018-11-14 |
| 2017-06-30 | $39.00K 10-Q · filed 2018-08-14 |
| 2017-03-31 | $235.00K 10-Q · filed 2018-05-15 |
| 2016-12-31 | $19.00K 10-K · filed 2019-03-29 |
| 2016-09-30 | $154.00K 10-Q/A · filed 2018-02-28 |
| 2016-06-30 | $355.00K 10-Q/A · filed 2018-02-28 |
| 2016-03-31 | $30.00K 10-Q/A · filed 2018-02-28 |
| 2015-12-31 | $47.00K 10-K · filed 2018-03-01 |
| 2015-09-30 | $42.00K 10-Q/A · filed 2018-02-28 |
| 2015-06-30 | $125.00K 10-Q/A · filed 2018-02-28 |
| 2015-03-31 | $1.42M 10-Q/A · filed 2018-02-28 |
| 2014-12-31 | $855.00K 10-K/A · filed 2018-02-28 |
| 2014-09-30 | $664.00K 10-Q · filed 2015-11-13 |
| 2014-06-30 | $1.00K 10-Q · filed 2015-08-14 |
| 2014-03-31 | $4.00K 10-Q · filed 2015-05-14 |
| 2013-12-31 | $43.00K 10-K/A · filed 2018-02-28 |
| 2013-09-30 | $0.00 10-Q · filed 2015-01-08 |
| 2013-06-30 | $11.00K 10-Q · filed 2015-01-08 |
| 2013-03-31 | $0.00 10-Q · filed 2015-01-08 |
| 2012-12-31 | $123.00K 10-K · filed 2015-03-31 |
| 2012-09-30 | $61.00K 10-K · filed 2015-01-08 |
| 2012-06-30 | $5.00K 10-Q · filed 2014-12-12 |
| 2012-03-31 | $120.00K 10-Q · filed 2014-12-10 |
| 2011-12-31 | $92.00K 10-K · filed 2015-01-08 |
| 2011-09-30 | $0.00 10-Q · filed 2012-11-21 |
| 2011-06-30 | $89.00K 10-Q/A · filed 2012-09-13 |
| 2011-03-31 | $1.00K 10-Q · filed 2012-05-21 |
| 2010-12-31 | $54.00K 10-K · filed 2014-11-18 |
| 2010-09-30 | $181.00K 10-Q · filed 2011-11-21 |
| 2010-06-30 | $571.00K 10-Q/A · filed 2011-09-12 |
| 2009-12-31 | $1.29M 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |